cyclophosphamide / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

353 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cyclophosphamide / Generic mfg.
2015-000832-13: Ibrutinib for untreated mantle cell lymphoma

Ongoing
2/3
400
Europe
Ibrutinib, Rituximab, Bendamustine hydrochloride, Cyclophosphamide, Doxorubicin hydrochloride, Vincristine sulphate, Prednisolone, Capsule, hard, Concentrate for solution for injection/infusion, Lyophilisate for solution for infusion, Powder for solution for infusion, Solution for infusion, Solution for injection, Tablet, Ibrutinib, doxorubicin
Plymouth Hospitals NHS Trust, Cancer Research UK, Janssen Pharmaceutica NV
Untreated symptomatic Mantle Cell Lymphoma, Untreated symptomatic Mantle Cell Lymphoma, Diseases [C] - Cancer [C04]
 
 
2014-002146-44: Blood cancer in younger adults (18-59 years) Cancer du sang de l'adulte jeune (18-59 ans)

Ongoing
2/3
1040
Europe
Atriance, Tasigna, cyclophosphamide, méthotrexate, vincristine, cytarabine, Etoposide, dexamethasone, prednisone, 6-mercaptopurine, daunorubicine, idarubicine, L-Asparaginase, G-CSF, imatinib, BLINATUMOMAB, Nélarabine, Nilotinib, Solution for infusion, Capsule, Powder for injection, Solution for injection, Tablet, Powder for infusion, Powder and solvent for solution for injection, Powder for concentrate and solution for solution for infusion, Atriance, Tasigna, cyclophosphamide, méthotrexate, vincristine, cytarabine, Etoposide, dexamethasone, prednisone, 6-mercaptopurine, daunorubicine, idarubicine, L-Asparaginase, G-CSF, imatinib, Blincyto
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP), DGOS
Patients with de novo acute lymphoblastic leukemia of young adults. -GRAALL-2014/B: Ph- B lineage ALL -GRAALL-2014/T et ATRIALL: T-ALL -GRAAPH-2014: ALL Ph+ Patients présentant une Leucémie Aigue Lymphoblastique de l'adulte jeune de novo. -GRAALL-2014/B : LAL de la lignée B Ph- -GRAALL-2014/T et ATRIALL : LAL T -GRAAPH-2014 : LAL Ph+, Acute Lymphoblastic Leukemia Leucémie Lymphoblastique Aigüe, Diseases [C] - Cancer [C04]
 
 
2006-006395-37: A randomised, multi-centre feasibility trial in AL Amyloidosis, comparing CTD with SCT in patients with low risk of Treatment Related Mortality and CTD with Mel-Dex in patients in whom SCT would not be considered appropriate as first line therapy

Ongoing
2/3
48
Europe
Cyclophosphamide, Dexamethasone, Melphalan, Thalidomide, Lenogastrim, Lenogastrim
Joint UCLH and UCL Biomedical Research Unit
The medical condition to be investigated is systemic AL Amyloidosis, a disorder of protein folding in which normally soluble proteins are deposited as abnormal, insoluble fibrils that progressively disrupt tissue structure and impair function.
 
 
2008-006710-23: Modulation of the immune response in patients with pancreatic tubular carcinoma

Ongoing
2/3
30
Europe
Pripravek MNC za zdravljenje, MIS_MIT, ENDOXAN 50 mg obložene tablete, ENDOXAN 50 mg obložene tablete
Blood Transfusion Centre of Slovenia
Pancreatic adenocarcinoma; after R0 or R1 resection and adjuvant gemcitabine treatment.
 
 
NCT00872508: Scleroderma: Cyclophosphamide or Transplantation (SCOT) Substudy 03

Not yet recruiting
2/3
60
US, Canada
Peripheral blood collection
National Institute of Allergy and Infectious Diseases (NIAID)
Scleroderma, Systemic, Sclerosis
03/16
03/16
ACTRN12617001516370: MOM trial. MOntelukast Myeloma A pilot study to determine whether Montelukast added to standard Chemotherapy improves response in patients who have failed standard Chemotherapy for Multiple Myeloma.

Active, not recruiting
2/3
6
 
Dr Stephen Kenneth O'Mara, Dr Stephen O'Mara
Multiple Myeloma
 
 
PREDIX HER2, NCT02568839 / 2014-000808-10: Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer

Active, not recruiting
2/3
202
Europe
docetaxel + trastuzumab sc + pertuzumab, Herceptin SC, Perjeta, trastuzumab emtansin, Kadcyla
Thomas Hatschek, Dept. of Oncology, Karolinska University Hospital
Early-Stage Breast Carcinoma, HER-2 Positive Breast Cancer
02/19
02/29
ARST1321, NCT02180867: Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Checkmark Data from ARST1321 trial in unresected intermediate-grade or high-grade soft tissue sarcoma
Jul 2020 - Jul 2020: Data from ARST1321 trial in unresected intermediate-grade or high-grade soft tissue sarcoma
Active, not recruiting
2/3
140
Canada, US
Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Pazopanib, GW786034, Pazopanib Hydrochloride, GW786034B, Pazopater, Votrient, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Therapeutic Conventional Surgery
National Cancer Institute (NCI)
Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Cutaneous Granular Cell Tumor, Malignant Peripheral Nerve Sheath Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
06/19
12/24
ADAPT, NCT01779206: - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

Checkmark Results from ADAPT study for HR+, HER2+ early breast cancer at ESMO 2021
Sep 2021 - Sep 2021: Results from ADAPT study for HR+, HER2+ early breast cancer at ESMO 2021
Active, not recruiting
2/3
4936
Europe
Epirubicin, Cyclophosphamide, Docetaxel, Paclitaxel
West German Study Group
Breast Cancer
09/19
10/24
2019-001261-33: Study of Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as initial therapy for Waldenström's macroglobulinaemia

Not yet recruiting
2/3
148
Europe
Ibrutinib, Rituximab, Dexamethasone, Cyclophosphamide, Capsule, hard, Concentrate for solution for infusion, , Ibrutinib, Rituximab, Dexamethasone, Cyclophosphamide
University College London
Waldenström's macroglobulinaemia, a blood cancer, Diseases [C] - Cancer [C04]
 
 
NCT01228331 / 2009-012758-18: Clofarabine or High-Dose Cytarabine and Pegaspargase in Children With ALL

Active, not recruiting
2/3
745
Europe
Amsacrine, Clofarabine, Cyclophosphamide, Cytarabine, Daunorubicin hydrochloride, Dexamethasone, Doxorubicin hydrochloride, Etoposide phosphate, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Thioguanine, Vincristine sulfate, Whole-brain radiation therapy
Universitätsklinikum Hamburg-Eppendorf
Leukemia
12/19
12/24
2019-001258-25: A phase II and phase III trial comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma suitable for stem cell transplant (TE)

Ongoing
2/3
1400
Europe
Isatuximab, Revlimid (Lenalidomide), Cyclophosphamide, Dexamethasone, Bortezomib, L04AX04, Solvent for solution for infusion, Capsule, hard, Tablet, Solution for injection, Kyprolis, Revlimid (Lenalidomide), Cyclophosphamide, Dexamethasone, Bortezomib
University of Leeds, Cancer Research UK, Sanofi S.A, Celgene Corporation
Newly diagnosed multiple myeloma, Multiple myeloma, Diseases [C] - Cancer [C04]
 
 
SCRRYST, NCT06341998: Clinical Study of Chemotherapy in the Treatment of Recurrent/Refractory Yolk Sac Tumor in Children

Completed
2/3
32
RoW
sirolimus combined with chemotherapy in the treatment of recurrent/refractory yolk sac tumor in children
Shandong First Medical University
Germ Cell Tumor, Yolk Sac Tumor
01/24
02/24
NCT01595048 / 2010-019224-31: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia

Active, not recruiting
2/3
640
US, Canada, RoW
Rituximab, MOAB IDEC-C2B8, Prednisone, Etoposide, Lastet, Doxorubicin Hydrochloride, Cytarabine, CHX-3311, U-19920, Vincristine Sulfate, Kyocristine, Oncovin, VCR, Vincasar, Cyclophosphamide, Methotrexate, Methylprednisolone, MePRDL, Leucovorin Calcium, CF, Therapeutic Hydrocortisone, Aeroseb-HC, Cetacort, HC, Laboratory Biomarker Analysis
Children's Oncology Group, National Cancer Institute (NCI)
Childhood B Acute Lymphoblastic Leukemia, Childhood Burkitt Leukemia, Childhood Diffuse Large Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma
12/20
12/20
FORUM, NCT01949129 / 2012-003032-22: Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Recruiting
2/3
1800
Europe, Canada, RoW
VP16, Etoposide, TBI, Thiotepa, Thio, Treosulfan, Treo, Fludarabine, Flu, Busulfan, Bu, ATG Thymoglobulin, ATG Thymo, Cyclophosphamide, Cy, Grafalon, Anti-human T-lymphocyte immunoglobulin
St. Anna Kinderkrebsforschung, ALL SCTped Forum, European Society for Blood and Marrow Transplantation, ALL-BFM Study Group, Assistance Publique - Hôpitaux de Paris, Dutch Childhood Oncology Group, Swiss Pediatric Oncology Group, Australian & New Zealand Children's Haematology/Oncology Group
Acute Lymphoblastic Leukaemia
06/25
04/30
NCT03818334: Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies

Recruiting
2/3
50
RoW
Cyclophosphamide, Cytoxan, ATG, Thymoglobulin
Hospital Israelita Albert Einstein
Bone Marrow Transplant Complications, Graft Versus Host Disease, Infection Viral, Engraft Failure, Immunologic Suppression
11/21
11/26
NCT03799224: Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia

Recruiting
2/3
55
RoW
Decitabine, mBU/CY and ATG, mBU/CY
Peking University People's Hospital
Stem Cell Transplant Complications, Relapse Leukemia, Refractory Leukemia
12/21
12/23
NCT04290793: Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Not yet recruiting
2/3
280
NA
Pyrotinib, Epirubicin, Cyclophosphamide, Taxanes, Trastuzumab
Hebei Medical University Fourth Hospital
Breast Cancer
03/22
03/24
NCT04387630: Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.

Recruiting
2/3
120
RoW
Metformin, Glucophage, Placebo oral tablet
Mansoura University
Breast Cancer
06/22
05/23
NCT04098653: Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT

Recruiting
2/3
196
RoW
Decitabine, Busulfan (BU), Cyclophosphamide (CY)
Nanfang Hospital of Southern Medical University, Peking University People's Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Third Affiliated Hospital, Sun Yat-Sen University, Zhujiang Hospital
Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myeloid Tumors
08/22
08/23
NCT04123392: Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT

Recruiting
2/3
196
RoW
Decitabine, Busulfan (BU), Cyclophosphamide (CY)
Nanfang Hospital of Southern Medical University, Peking University People's Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Third Affiliated Hospital, Sun Yat-Sen University, Zhujiang Hospital
TP53, Myeloid Tumors, Conditioning, Allogeneic Hematopoietic Stem Cell Transplantation
09/22
09/23
NCT04753177: The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Advanced ER+/HER2- Breast Cancer

Active, not recruiting
2/3
120
RoW
Ribocyclib, fulvestrant, triptorelin, Doxorubicin, cyclophosphamide, paclitaxel
Saint Petersburg State Budgetary Healthcare Institution, City Clinical Oncology Dispensary
The Neoadjuvant Therapy
01/23
01/24
NCT04257175: CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression

Recruiting
2/3
10
RoW
CAR-T CD19
Sheba Medical Center
Acute Myeloid Leukemia
12/24
12/24
NCT05553496: Assessment of Rituximab Therapeutic Response Versus Conventional Treatment

Not yet recruiting
2/3
40
NA
Rituximab, Dexamethasone, Tacrolimus, Mycophenloatemofetil, Cyclophosphamide, Cyclosporine
Ain Shams University
Pharmacological Action
04/23
10/23
NCT06324266: Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation

Recruiting
2/3
80
RoW
Cyclophosphamide, CTX, Lenalidomide, Len
Jinling Hospital, China
Newly Diagnosed Multiple Myeloma
12/25
12/25
NCT05595109: Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients

Enrolling by invitation
2/3
56
RoW
Silymarin, Placebo
Tanta University
Breast Cancer, Peripheral Neuropathy, Cardiac Toxicities, Hepatic Toxicity, Cognitive Impairment
04/23
10/24
neo-TN, NCT01057069 / 2009-015238-31: Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer

Active, not recruiting
2/3
310
Europe
Carboplatin and Paclitaxel, Carboplatin, Paclitaxel, Doxorubicin, cyclophosphamide, Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide
The Netherlands Cancer Institute
Breast Cancer
06/23
12/29
NCT04576143: Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Recruiting
2/3
260
RoW
Epirubicin, Epirubicin Hydrochloride, Cyclophosphamid, CTX, Docetaxel, Paclitaxel, PTX
Second Affiliated Hospital, School of Medicine, Zhejiang University, Women's Hospital School Of Medicine Zhejiang University, Changxing People's Hospital, Zhejiang Provincial People's Hospital, Hangzhou First People's Hospital, School of Medicine, Zhejiang Universiry, Huizhou Municipal Central Hospital
HER2-negative Breast Cancer, Neoadjuvant Chemotherapy
06/23
09/27
NCT04713956: G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Recruiting
2/3
242
RoW
Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU), Cyclophosphamide (CY), Fludarabine (FLU)
Nanfang Hospital of Southern Medical University, Peking University People's Hospital, Institute of Hematology and Blood Diseases Hospital, Guangzhou First People's Hospital, Third Affiliated Hospital, Sun Yat-Sen University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First People's Hospital of Chenzhou, First Affiliated Hospital of Guangxi Medical University
Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning
07/23
07/24
PDT-Ph-Like, NCT03564470: Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

Recruiting
2/3
120
RoW
Chidamide, HDACi chidamide, Dasatinib, TKI dasatinib
Nanfang Hospital of Southern Medical University
Leukemia, Leukemia, Acute, Leukemia, Lymphoblastic, Leukemia, B-cell
08/23
08/23
NCT01046825: Mature B-Cell Lymphoma And Leukemia Study III

Active, not recruiting
2/3
128
US, RoW
COPAD, VCR, prednisone, Adriamycin, cytoxan, filgrastim, Neupogen, Neulasta®, COP, COPD M3, CYM, Elitek, Cytoxan, MTX, folinic acid, Rituxan, Ara-C, COP, COPADM8, CYVE, VP16
St. Jude Children's Research Hospital
Mature B-Cell Lymphoma
08/23
08/27
NCT03793517: Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT

Recruiting
2/3
55
RoW
Decitabine, mBU/CY and ATG, mBU/CY
Peking University People's Hospital
Stem Cell Transplant Complications, Leukemia, Myeloid, Acute, Leukemia Relapse
10/23
10/26
BNHL-2015, NCT02405676: for Children or Adolescents in China

Active, not recruiting
2/3
200
RoW
Prednisone,Vincristine, Cyclophosphamide, Preface, Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone, Protocol A, Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone, Protocol B, Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone, Protocol AA, Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone, Protocol BB, Rituximab
Children's Cancer Group, China, Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology, China, Nanjing Children's Hospital, West China Second University Hospital, Xiangya Hospital of Central South University, Qilu Hospital of Shandong University, Children's Hospital of Soochow University, Tianjin Medical University Cancer Institute and Hospital
Mature B-cell Non-Hodgkin Lymphoma
12/23
12/24
BCTOP-T-A01, NCT02641847: TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Active, not recruiting
2/3
503
RoW
docetaxel, doxorubicin or epirubicin, cyclophosphamide, gemcitabine, cisplatin
Fudan University
Triple Negative Breast Cancer, Breast Cancer
12/23
12/27
NCT05449899: G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT

Recruiting
2/3
232
RoW
Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU), Fludarabine (FLU), Cyclophosphamide (CY)
Nanfang Hospital of Southern Medical University, Peking University People's Hospital, Institute of Hematology and Blood Diseases Hospital, Guangzhou First People's Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First People's Hospital of Chenzhou, The Seventh Affiliated Hospital of Sun Yat-sen University
Secondary Acute Myeloid Leukemia Evolving From MDS, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning
12/23
12/24
NCT05453552: G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT

Recruiting
2/3
242
RoW
Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan, Fludarabine (FLU), Cyclophosphamide (CY), Busulfan (BU)
Nanfang Hospital of Southern Medical University, Peking University People's Hospital, Institute of Hematology & Blood Diseases Hospital, Guangzhou First People's Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, First People's Hospital of Chenzhou, The Seventh Affiliated Hospital of Sun Yat-sen University
Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning
12/23
12/24
NCT06475820: Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Recruiting
2/3
150
RoW
Baricitinib, Vedolizumab, Abatacept, Cyclophosphamide
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma, Myelodysplastic Syndromes
12/26
04/27
NCT03418779: Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD

Active, not recruiting
2/3
60
RoW
The Yi-Qi-Qing-Jie herbal compound, Immunosuppressants, prednisolone, cyclophosphamide, Optimized Supportive Care, Yi-Qi-Qing-Jie herbal compound placebo
Guang'anmen Hospital of China Academy of Chinese Medical Sciences, China Academy of Chinese Medical Sciences
IgA Nephropathy at High Risk of Developing ESRD
12/23
12/24
NCT04620772: Cyclophosphamide in the Treatment of Refractory Proliferative Arachnoiditis in CNS Tuberculosis

Not yet recruiting
2/3
40
NA
Cyclophosphamide injection
All India Institute of Medical Sciences, New Delhi
Tuberculosis, Tubercular Meningitis, Arachnoiditis; Tuberculous (Etiology)
12/23
12/24
NCT05739630: M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia

Recruiting
2/3
60
RoW
mitoxantrone liposome, Fludarabine,Cytarabine,busulfan,Cyclophosphamide,MMF,Tacrolimus Capsules, ATG, MECCNU,Hu,Cytarabine,busulfan,Cyclophosphamide,MTX,CsA
The First Affiliated Hospital of Soochow University
Acute Leukemia
01/24
01/25
NCT03937544: Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

Recruiting
2/3
10
RoW
CD19 CAR-T CELLS, Cyclophosphamide, Fludarabine
National University of Malaysia, Gaia Science
Relapsed B Acute Lymphoblastic Leukaemia, Refractory B Acute Lymphoblastic Leukaemia
03/24
03/24
RAINBOW, NCT04061512: Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia

Recruiting
2/3
148
Europe
Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib
University College, London, Janssen-Cilag Ltd.
Waldenstrom Macroglobulinemia
03/30
03/30
ChiCTR2200064513: A prospective single arm multicenter study of immune tolerance induced by modified post cyclophosphamide combined with mycophenolate mofetil after allogeneic peripheral blood stem cell transplantation

Recruiting
2/3
50
 
try regimen
Xiangya Hospital of Central South University; Xiangya Hospital of Central South University, Medical Technology Clinical Research Projects from Xiangya Hospital, Central South University
NA
 
 
NeoHTerMa, NCT05889390: Neoadjuvant Concomitant Modulated Electro-hyperthermia in HER2-negative Breast Cancer

Recruiting
2/3
120
Europe
Oncotherm EHY-2030, Paclitaxel, Carboplatin, Cyclophosphamide/Doxorubicin, Breast cancer removal surgery
Semmelweis University
HER2-negative Breast Cancer
12/24
04/25
NCT06009627: Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients

Recruiting
2/3
119
RoW
Dalcelli、Exemestane、Gosserine, Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection
Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
03/25
09/26
NCT04799275: Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Recruiting
2/3
422
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Oral Azacitidine, Azacitidine Oral, CC-486, Onureg, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Questionnaire Administration, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 3b Follicular Lymphoma, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Nodular Lymphocyte Predominant B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
03/26
03/26
NCT04220190: RAPA-501 Therapy for ALS

Not yet recruiting
2/3
41
US
RAPA-501 Autologous T cells, RAPA-501 cells
Rapa Therapeutics LLC, Massachusetts General Hospital, Hackensack Meridian Health
Amyotrophic Lateral Sclerosis
07/25
07/25
NCT03759093: CURATE.AI Optimized Modulation for Multiple Myeloma

Recruiting
2/3
20
RoW
Bortezomib, Velcade, Cyclophosphamide, Dexamethasone, CURATE.AI-Guided dosage modulation, Thalidomide, Lenalidomide, Revlimid
National University Hospital, Singapore, National University of Singapore
Multiple Myeloma
09/25
09/25
NCT03117751: Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Active, not recruiting
2/3
790
US, RoW
Prednisone, Prednisolone, Deltasone, Meticorten, Orasone®, Liquid Pred, Pediapred®, Sterapred®, Vincristine, Vincristine sulfate, Oncovin®, VCR, LCR, Daunorubicin, Daunomycin, rubidomycin, Cerubidine®, Pegaspargase, PEG-asparaginase, PEGLA, PEG-L-asparaginase, polyethylene glycol-L-asparaginase, Oncaspar®, Erwinase®, Erwinia chrysanthemi, Asparaginase Erwinia chrysanthemi, Erwinaze^TM, Crisantaspase, Cyclophosphamide, Cytoxan®, Cytarabine, Cytosine arabinoside, Ara-C, Cytosar®, Mercaptopurine, 6-MP, Purinethol®, Purixan^TM, 6-mercaptopurine, Dasatinib, Sprycel®, Methotrexate, MTX, amethopterin, Trexall®, Blinatumomab, Blincyto®, Ruxolitinib, Jakafi®, Bortezomib, Velcade®, Dexamethasone, Decadron®, Hexadrol®, Dexone®, Dexameth®, Doxorubicin, Adriamycin®, Etoposide, Etoposide Phosphate, VePesid®, Etopophos®, VP-16, Clofarabine, Clolar®, Vorinostat, Zolinza®, Suberoylanilide Hydroxamic Acid, SAHA, Idarubicin, Idarubicin HCl, 4-Demethoxydaunorubicin, 4-DMD, DMDR, Idamycin PFS®, Nelarabine, Arranon®, Atriance®, Compound 506U78, Thioguanine, 6-thioguanine, Tioguanine, 2-amino-1,7-dihydro-6H-purine-6-thione, WR-1141, Tabloid®, Lanvis®, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Rylaze™, Recombinant Erwinia, Calaspargase Pegol, ASPARLAS
St. Jude Children's Research Hospital, Incyte Corporation, Amgen, Servier
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
09/26
03/28
NCT02066220 / 2011-004868-30: International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma

Active, not recruiting
2/3
360
Europe, RoW
Radiotherapy without Carboplatin, Reduced-intensity maintenance chemotherapy, Cisplatin, Lomustin (CCNU), Vincristine, Cyclophosphamide, Radiotherapy with Carboplatin, Carboplatin, Maintenance chemotherapy, Lomustine (CCNU), WNT-HR < 16 years, WNT-HR >= 16 years, Induction Chemotherapy, SHH-TP53 M0, SHH-TP53 M+ (germline), SHH-TP53 (somatic), Vinblastin Maintenance
Universitätsklinikum Hamburg-Eppendorf, Deutsche Kinderkrebsstiftung
Brain Tumors
12/26
12/26
A051701, NCT03984448: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

Active, not recruiting
2/3
363
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Lumbar Puncture, LP, Spinal Tap, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, Perrigo Prednisone, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisone Intensol, Prednisonum, Prednitone, Promifen, Rayos, Servisone, SK-Prednisone, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
04/28
04/28
SIOP-EP-II, NCT02265770 / 2013-002766-39: An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma

Recruiting
2/3
536
Europe, RoW
16 weeks of VEC + CDDP, Vincristine, Etoposide, Cyclophosphamide, Cisplatin, VEC + HD-MTX, Methotrexate, Chemotherapy + Valproate, Carboplatin, Valproate, Conformal radiotherapy, VEC, Chemotherapy, conformal radiotherapy +/- boost
Centre Leon Berard
Childhood Ependymoma
06/28
08/31
REPROGRAM-02, NCT05462613: Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer

Recruiting
2/3
446
Europe
quality of life questionnaires, Blood sample, Regorafenib, Metronomic chemotherapies, Aspirin, Bevacizumab, FOLFIRI or FOLFOX
Centre Hospitalier Universitaire de Besancon
Metastatic Colorectal Cancer
11/29
11/30
 

Download Options